This technology is a modified CRISPR/Cas9 gene editing therapy that is mutation-independent for treating autosomal dominant disease-related genes, including retinitis pigmentosa.
This technology is an artificial intelligence-based platform for improving the quality of images taken from portable OCT devices and detecting age-related macular degeneration.
This technology is a collection of optimized therapeutic prime-editing strategies targeting four common splicing mutations in the peripherin‐2 gene (PRPH2) that are associated with various retinal degenerations.
This technology uses a femtosecond laser to crosslink collagen and can be used as treatment for repair of collagenous tissues such as cornea and cartilage.
This technology is a method of reprogramming cellular metabolism to treat neurodegenerative disorders by downregulating catabolism and upregulating anabolism in cells.
This technology is a gene therapy which delivers CRB1 isoforms to their cell-specific localizations, for the treatment of retinopathies caused by CRB1 mutations.
This technology is an AAV-mediated BEST1 gene therapy for the treatment of retinal degenerative disorders associated with Bestrophin-1 (BEST1) dominant mutations.
This technology uses S-methyl-L-Thiocitrulline, a neuronal nitric oxide synthase inhibitor, and its derivatives as a pharmacological treatment for the prevention and treatment of myopia.
This technology uses CRISPR-Cas gene editing to disrupt and correct ocular disease-associated mutated genes, resulting in improved protein function and disease treatment.
This technology is a naturally occurring non-coding RNA that regulates the SLC2A1 gene, allowing for therapeutic regulation of Glut1 for treatment of diseases in which Glut1 is under-expressed.
This technology is a generally applicable gene therapy approach that restores metabolic dysregulation and treats retinal degenerative diseases regardless of genetic variation.
This technology is a class of small-molecule antagonists that prevents visual loss associated with Stargardt disease by downregulating serum retinol to inhibit the accumulation of cytotoxic A2E in the retina.
This technology is a structural class of transthyretin (TTR) ligands that can be used to simultaneously treat dry age-related macular degeneration (AMD) and wild-type transthyretin amyloidosis (ATTRwt).
